BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 26, 2008
View Archived Issues
New treatment options for cancer disclosed in patent literature
Read More
Cadence completes registered direct offering of shares for USD 49.3 million
Read More
Lilly launches the KwikPen insulin pen prefilled with Humalog and Humalog mixtures
Read More
Preclinical profile of novel radioligand for Abeta imaging in Alzheimer's disease
Read More
Vertex advances key programs in fourth quarter
Read More
Prostate-specific membrane antigen DNA vaccine safe in renal cell carcinoma patients
Read More
MK-0343 has different effects on healthy volunteers than lorazepam
Read More
Nycomed acquires Bradley Pharmaceuticals
Read More
Laboratory Corporation reports phase II results for ovarian cancer blood test
Read More
FDA grants IND approval to Algeta for Alpharadin for hormone-refractory prostate cancer
Read More
Mitsubishi Tanabe updates recent pipeline developments
Read More
FDA approves Kiadis Pharma's IND application for phase III clinical study of Reviroc
Read More
CHMP issues positive opinion for Mycamine
Read More
Reduced spinal cord opioid receptor mRNA and antinociception in MS mouse model
Read More
Rosiglitazone neuroprotective mechanism in experimental stroke elucidated
Read More
JuvImmune protects mice against lethal pneumonic infection
Read More
Top-line results do not meet primary endpoint in phase III MEND-CABG II trial
Read More
Biofrontera initiates phase II BF-37 study for psoriasis
Read More
Eucreas, a single-tablet combination of Galvus and metformin, approved in EU
Read More
Phase III AZ-004 trial begins in patients with schizophrenia or bipolar disorder
Read More
Novel agents for lipoprotein disorders imparted in a recent patent
Read More
Positive preliminary results reported from MacuSight's phase I sirolimus study
Read More
Recent patents report new psychopharmacologic agents
Read More
Akesis commences AKP-020 dosing in phase IIa clinical trial in type 2 diabetes
Read More
Recruitment starts for clinical phase III trial of K-301 in seborrheic dermatitis
Read More